News
-
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
LIR Life Sciences Corp. announces successful completion of comparative mouse study evaluating skin-permeation delivery of GLP/GIP-based therapies. Results presented at ENDO 2026 -
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Neuland Laboratories Limited orders raw materials for Phase 1 of macromolecule-enabled transdermal delivery development with LIR Life Sciences Corp. to advance needle-free, skin-applied peptide therapies -
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules
LIR Life Sciences Corp. announces the launch of a controlled ex vivo porcine skin study to evaluate protamine's impact on transdermal movement of macromolecular therapeutics. The study aims to advance needle-free delivery options for larger molecules -
